Pan-cancer analysis of ADAR1 with its prognostic relevance in low-grade glioma
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Adenosine-to-inosine RNA editing enzyme ADAR1 plays a role in cancer. A new 3-gene signature including ADAR, HNRNPK, and SMG7 can predict patient outcomes, especially in low-grade glioma.
Area Of Science
- Oncology
- Molecular Biology
- Genetics
Background
- Adenosine-to-inosine RNA editing enzyme ADAR1 is implicated in cancer via RNA editing-dependent and -independent pathways.
- ADAR1's functions extend beyond current understanding, necessitating pan-cancer analysis for personalized medicine.
- Low-grade glioma (LGG) risk stratification is challenging due to tumor cell diversity.
Purpose Of The Study
- Analyze ADAR mRNA expression across multiple cancers.
- Determine the prognostic significance of ADAR in LGG.
- Develop a gene signature for risk stratification and outcome prediction.
Main Methods
- Pan-cancer analysis of ADAR mRNA and protein expression.
- Correlation analysis with genetic alterations, tumor mutation burden, and microsatellite instability.
- Cox proportional hazards model to develop a 3-gene signature (ADAR, HNRNPK, SMG7).
Main Results
- Inconsistent ADAR mRNA and protein expression patterns observed across tumor types.
- ADAR mRNA levels correlated significantly with survival, immune markers, and immunotherapy response in select cancers.
- The 3-gene signature stratified patients into high- and low-risk groups with distinct survival outcomes and tumor characteristics.
Conclusions
- ADAR1 has multifaceted roles in cancer, with significant prognostic value in LGG.
- The developed 3-gene signature offers potential for improved risk stratification and outcome prediction in LGG.
- Findings provide insights into potential therapeutic targets and strategies involving ADAR1 and associated genes.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...